Regulation of Compounded Weight-Loss Medication
SB066 regulates the sale, transfer, distribution, labeling, advertising, and recordkeeping for compounded weight-loss medications that are not FDA-approved, with a particular focus on compounded GLP-1 drugs used for obesity or weight management. The bill allows these products to be sold only if the compounder verifies a series of sourcing and quality standards, including use of appropriate bulk drug substances, pharmaceutical-grade ingredients, valid certificates of analysis, FDA registration of the manufacturing facility, and recent FDA inspection results. It also requires pre-sale quality control testing of bulk ingredients and prohibits distribution of counterfeit, adulterated, misbranded, diverted, or otherwise unlawful products.
The bill would add a new section to Colorado consumer protection law, creating state-level standards for compounded weight-loss medications and giving the attorney general exclusive enforcement authority under the Colorado Consumer Protection Act. It would require specific warning labels and patient disclosures, ban false or misleading advertising claims, mandate retention of records for at least two years, and authorize inspections of relevant premises. Violations could result in fines of up to $1,000 per dose or package unit and possible license revocation by the state board of pharmacy, while also clarifying that no private right of action is created. The bill applies only to entities compounding more than 20 units per month or in batches over 20 units, and it excludes certain care settings and animal-use compounding.
The bill appears to have been motivated by concern over patient safety, product integrity, and misleading marketing in the rapidly growing market for compounded weight-loss drugs. The legislative declaration frames the measure as a consumer-protection and public-health response to non-FDA-approved products and emphasizes the need for clearer information and stronger oversight. Voting history suggests the bill was controversial in the Senate Health & Human Services Committee, where it advanced on a narrow 5-4 vote, but it later passed Senate third reading 19-15 after a 34-0 third-reading amendment vote. In the House, however, the bill was postponed indefinitely in the House Health & Human Services Committee on a 12-0 vote, indicating the measure did not ultimately gain traction there.
The main points of contention are the bill’s regulatory burden on compounding pharmacies and wholesalers versus the public-health rationale for tighter oversight. Supporters are likely to view the bill as necessary to prevent unsafe, unverified, or misleading compounded GLP-1 products from reaching patients, while critics may argue that the requirements are too restrictive, could limit access to weight-loss treatments, and may interfere with legitimate compounding practices. The narrow committee vote in the Senate suggests disagreement over whether the state should impose these standards beyond existing federal rules, and the House committee’s decision to postpone indefinitely indicates unresolved concerns about the bill’s scope, enforceability, or impact on the compounding industry.